ArticleJournal of industrial microbiology & biotechnology2024
A Multi Clone Kinetic Model for characterizing Chinese hamster ovary cell line variability.
Article in Journal of industrial microbiology & biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This paper presents the Multi Clone Kinetic Model (MCKM), a novel generalized kinetic mechanistic model for fed-batch cultivations of diverse Chinese hamster ovary (CHO) cell lines, producing different recombinant monoclonal antibodies (mAbs). Unlike traditional kinetic models requiring multiple cultures for one parameter regression, MCKM derives a complete set of 13 kinetic parameters from a single fed-batch cell line culture of 49 data points. This enables per-cell-line metabolic characterization during cell line development, as well as direct comparisons of kinetics across clones, passages, and different recombinant mAbs. To enable MCKM to be broadly applicable across many cell lines and mAbs, and to address the high-dimensional challenge of estimating 13 kinetic parameters from a small number of datapoints, the model uniquely incorporates a mechanistic growth constraint, a glucose-dependent lactate switch, and automated parameter balancing. MCKM demonstrated successful regression of 656 fed-batch culture runs of 157 unique CHO cell lines across four passage generations, recombinant for three different mAbs, achieving high accuracy in biomass and mAb titre (average ${\rm{\bar{R}}}_{{{{\rm{X}}}_{\rm{v}}}}^2$ ≈ 0.96 ± 0.07 and ${\rm{\bar{R}}}_{\rm{P}}^2$ ≈ 0.97 ± 0.05, respectively). MCKM could facilitate automated cell line selection, identification of critical process parameters and biomarkers, guide media and feeding strategies, predict metabolite profiles, and support scale-up and quality-by-design studies, delivering overall reduction of experimental workload. One-Sentence Summary: This paper presents a novel kinetic model that derives distinct parameter sets from a single fed-batch run, enabling characterization of individual CHO clones across different mAb targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.